prikaz prve stranice dokumenta External Validation of UDCA Response Score in Slovak and Croatian Patients with Primary Biliary Cholangitis
  Download
PDF 1.24 MB
Scientific paper - Original scientific paper
External Validation of UDCA Response Score in Slovak and Croatian Patients with Primary Biliary Cholangitis
Canadian Journal of Gastroenterology and Hepatology, 2021 (2021); 9928065. https://doi.org/10.1155/2021/9928065
Gazda, Jakub; Janicko, Martin; Drazilova, Sylvia; Grgurević, Ivica; Filipec Kanižaj, Tajana; Koller, Tomas; Bodorovska, Beatrica; Mijić, Maja; Mikolašević, Ivana; Stromar, Ivana Knežević; Kucinsky, Branislav; Gazda, Matej; Jarcuska, Peter

Institutional repository: Repository of the University of Rijeka, Faculty of Medicine

Cite this document

Gazda, J., Janicko, M., Drazilova, S., Grgurević, I., Filipec Kanižaj, T., Koller, T. ... Jarcuska, P. (2021). External Validation of UDCA Response Score in Slovak and Croatian Patients with Primary Biliary Cholangitis. Canadian Journal of Gastroenterology and Hepatology, 2021.. doi: 10.1155/2021/9928065

Gazda, Jakub, et al. "External Validation of UDCA Response Score in Slovak and Croatian Patients with Primary Biliary Cholangitis." Canadian Journal of Gastroenterology and Hepatology, vol. 2021, 2021. https://doi.org/10.1155/2021/9928065

Gazda, Jakub, Martin Janicko, Sylvia Drazilova, Ivica Grgurević, Tajana Filipec Kanižaj, Tomas Koller, Beatrica Bodorovska, et al. "External Validation of UDCA Response Score in Slovak and Croatian Patients with Primary Biliary Cholangitis." Canadian Journal of Gastroenterology and Hepatology 2021 (2021). https://doi.org/10.1155/2021/9928065

Gazda, J., et al. (2021) 'External Validation of UDCA Response Score in Slovak and Croatian Patients with Primary Biliary Cholangitis', Canadian Journal of Gastroenterology and Hepatology, 2021. doi: 10.1155/2021/9928065

Gazda J, Janicko M, Drazilova S, Grgurević I, Filipec Kanižaj T, Koller T, and sur.. External Validation of UDCA Response Score in Slovak and Croatian Patients with Primary Biliary Cholangitis. Canadian Journal of Gastroenterology and Hepatology [Internet]. 2021 [cited 2024 November 10];2021. doi: 10.1155/2021/9928065

J. Gazda, et al., "External Validation of UDCA Response Score in Slovak and Croatian Patients with Primary Biliary Cholangitis", Canadian Journal of Gastroenterology and Hepatology, vol. 2021, 2021. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:373905. [Accessed: 10 November 2024]

Metadata
Title (english)External Validation of UDCA Response Score in Slovak and Croatian Patients with Primary Biliary Cholangitis
AuthorJakub Gazda
AuthorMartin Janicko
AuthorSylvia Drazilova
AuthorIvica Grgurević
AuthorTajana Filipec Kanižaj
AuthorTomas Koller
AuthorBeatrica Bodorovska
AuthorMaja Mijić
AuthorIvana Mikolašević
AuthorIvana Knežević Stromar
AuthorBranislav Kucinsky
AuthorMatej Gazda
AuthorPeter Jarcuska
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
Background. Ursodeoxycholic acid response score (URS) is a prognostic model that estimates the baseline probability of treatment response after 12 months of ursodeoxycholic acid (UDCA) therapy in patients with primary biliary cholangitis (PBC). Aim. To independently evaluate the predictive performance of the URS model. Methods. We used a cohort of Slovak and Croatian treatment-naïve PBC patients to quantify the discrimination ability using the area under receiver operating characteristic curve (AUROC) and its 95% confidence interval (CI). Furthermore, we evaluated the calibration using calibration belts. The primary outcome was treatment response after 12 months of UDCA therapy defined as values of alkaline phosphatase ≤1.67 × upper limit of normal. Results. One hundred and ninety-four patients were included. Median pretreatment age was 56 years (interquartile range 49–62). Treatment response was achieved in 79.38% of patients. AUROC of the URS was 0.81 (95% CI 0.73–0.88) and the calibration belt revealed that response rates were correctly estimated by predicted probabilities. Conclusion. Our results confirm that the URS can be used in treatment-naïve PBC patients for estimating the treatment response probability after 12 months of UDCA therapy.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleCanadian Journal of Gastroenterology and Hepatology
Numberingvol. 2021, 9928065
p-ISSN2291-2789
e-ISSN2291-2797
DOIhttps://doi.org/10.1155/2021/9928065
URN:NBNurn:nbn:hr:184:373905
Publication2021
Document URLhttps://www.hindawi.com/journals/cjgh/2021/9928065/
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2022-09-16 13:14:09